Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.

Trial Details

NCT ID
NCT02926690
Phase
PHASE1
Sponsor
OncoTherapy Science, Inc.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • OTS167PO
Locations (sample)
  • Norwalk, Connecticut, United States|41.1176,-73.4079
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Honolulu, Hawaii, United States|21.30694,-157.85833
  • Lebanon, New Hampshire, United States|43.64229,-72.25176
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Dose Escalation and Dose Expansion Cohorts
  • Patients must meet all of the following criteria to be eligible for participation in the study:
  • Female patients, ≥ 18 years of age at the time of obtaining informed consent.
  • Patients with a documented (histologically- or cytologically-proven) breast cancer that is locally advanced or metastatic.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →